Bristol-Myers ends hepatitis C drug development

August 24, 2012

(AP)—Drugmaker Bristol-Myers Squibb Co. has scrapped a potential hepatitis C treatment after a patient participating in a test of the drug died of heart failure.

The New York company said Thursday that it decided to discontinue development of the drug, labeled BMS-986094, in the interest of .

The patient's prompted Bristol-Myers to voluntarily suspend a mid-stage study of the drug on Aug 1. The U.S. subsequently placed the drug on a clinical hold.

"The decision to halt development of BMS-986094 has been guided by our overriding interest in protecting patients," Elliott Sigal, Bristol-Myers' chief scientific officer, said in a statement.

Nine patients, including the one who died, were hospitalized. Two remain under hospital care, the company said.

Bristol-Myers said it hasn't definitively established what caused patients to become ill, but identified heart and kidney toxicity as a key factor.

The company said it is working with the FDA to monitor the patients involved in the study. It also said it would continue to investigate the potential cause of the drug's toxicity.

can prove fatal to experimental drugs. The FDA has been focusing more on those risks since & Co. took its painkiller Vioxx off the market several years ago after a study showed the drug doubled the risk of heart attack or stroke.

Bristol Myers has been pushing to become a player in the drug market, which is expected to grow as baby boomers get older.

The discontinued drug was one of two main potential hepatitis C treatments from Bristol-Myers that investors are focused on. The other is a compound labeled daclatasvir that has started late-stage testing, the last step before drugmakers submit a product to regulators for approval.

Bristol-Myers acquired BMS-986094 and some other potential treatments as part of a $2.5 billion acquisition of drug developer Inhibitex Inc. it completed earlier this year.

Hepatitis C is a virus that can lead to life-threatening liver damage and is the main cause of liver transplants in the United States. Analysts say the market for treatments is potentially lucrative for drugmakers. More people are expected to be diagnosed with the tough-to-treat disease as the baby boomer generation ages.

After a two-decade drought, the first two new hepatitis C drugs were approved last year: Victrelis from Merck & Co. and Incivek from Vertex Pharmaceuticals Inc. and Johnson & Johnson. Both significantly improve the cure rate over what has long been the standard of care, a mix of injections and pills with nasty, flu-like side effects that takes several months and still doesn't cure many patients.

' shares tumbled when it first announced earlier this month that it was suspending its trial of the C drug. In aftermarket trading Thursday, they added 5 cents to $32.20. The stock ended the regular trading session up 34 cents at $32.15.

Explore further: Bristol-Myers Squibb to buy Inhibitex for $2.5 billion

shares

Related Stories

Bristol-Myers Squibb to buy Inhibitex for $2.5 billion

January 8, 2012
Pharmaceutical giant Bristol-Myers Squibb Company announced it was acquiring Inhibitex, Inc., a company specializing in treatment of hepatitis C, for $2.5 billion (1.9 billion euros).

Bristol-Myers to buy diabetes drug maker for $5B

July 1, 2012
(AP) — Drug maker Bristol-Myers Squibb Co. says it agreed to buy diabetes drug maker Amylin Pharmaceuticals for about $5 billion in cash.

FDA questions safety of experimental diabetes drug

July 15, 2011
(AP) -- Federal health regulators have concerns about bladder and breast cancer seen in patients taking an experimental diabetes pill from Bristol-Myers Squibb and AstraZeneca.

Recommended for you

Mind-body therapies immediately reduce unmanageable pain in hospital patients

July 25, 2017
Mindfulness training and hypnotic suggestion significantly reduced acute pain experienced by hospital patients, according to a new study published in the Journal of General Internal Medicine.

Study suggests ending opioid epidemic will take years

July 20, 2017
The question of how to stem the nation's opioid epidemic now has a major detailed response. A new study chaired by University of Virginia School of Law Professor Richard Bonnie provides extensive recommendations for curbing ...

Team-based model reduces prescription opioid use among patients with chronic pain by 40 percent

July 17, 2017
A new, team-based, primary care model is decreasing prescription opioid use among patients with chronic pain by 40 percent, according to a new study out of Boston Medical Center's Grayken Center for Addiction Medicine, which ...

Private clinics' peddling of unproven stem cell treatments is unsafe and unethical

July 7, 2017
Stem cell science is an area of medical research that continues to offer great promise. But as this week's paper in Science Translational Medicine highlights, a growing number of clinics around the globe, including in Australia, ...

Popular heartburn drugs linked to higher death risk

July 4, 2017
Popular heartburn drugs called proton pump inhibitors (PPIs) have been linked to a variety of health problems, including serious kidney damage, bone fractures and dementia. Now, a new study from Washington University School ...

Most reproductive-age women using opioids also use another substance

June 30, 2017
The majority of reproductive-age and pregnant women who use opioids for non-medical purposes also use at least one other substance, ranging from nicotine or alcohol to cocaine, according to a University of Pittsburgh Graduate ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.